Dogwood Therapeutics DWTX Business Segments — Other Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's business segments — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's business segments — other research and development expense?
- Dogwood Therapeutics (DWTX) reported business segments — other research and development expense of $585.61K in Q1 2026.
- How has Dogwood Therapeutics's business segments — other research and development expense changed year-over-year?
- Dogwood Therapeutics's business segments — other research and development expense increased by 33.4% year-over-year, from $438.85K to $585.61K.
- What is the long-term trend for Dogwood Therapeutics's business segments — other research and development expense?
- Over 2 years (2023 to 2025), Dogwood Therapeutics's business segments — other research and development expense has grown at a 30.9% compound annual growth rate (CAGR), from $848.99K to $1.46M.
- What does business segments — other research and development expense mean?
- Encompasses miscellaneous research and development costs that do not fall into specific clinical, manufacturing, or regulatory categories. This may include overhead, general research support, or specialized consulting fees essential to the broader R&D function.